RCS - Thalia Therapeutics - CEO Interview: Thalia’s RNA Therapeutics Strategy
13/05/2026 11:15
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260513:nRSM1804Ea&default-theme=true
RNS Number : 1804E Thalia Therapeutics PLC 13 May 2026
13 May 2026
Thalia Therapeutics plc
("Thalia" or the "Company")
CEO Interview: Advancing Thalia's RNA Therapeutics Strategy
Thalia Therapeutics plc (AIM: THAT), a biotech company developing innovative
RNA therapeutics, is pleased to announce the release of a new video interview
with Chief Executive Officer, Dr David Solomon.
In the interview, Dr Solomon discusses the Company's strategic transition to
Thalia Therapeutics, the rationale behind its increasing focus on high-value
RNA therapeutics, the continued development of Nuvec®, and the opportunities
the Company sees in cardiovascular disease and oncology.
The interview is available to watch via the Company's website at:
https://investors.thaliatx.com/activity-updates
(https://investors.thaliatx.com/activity-updates)
- Ends -
For more information please contact:
Thalia Therapeutics plc
Dr David H Solomon, Chief Executive Officer Via Thalia Investor Hub
https://investors.thaliatx.com/link/P4zkAe
(https://investors.thaliatx.com/link/P4zkAe)
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44 (0)20 3657 0050
Joint Broker
Andy Thacker
Guy McDougall
Northstar Communications Tel: +44 (0)20 7183 2463
Investor relations and Communications
Sarah Hollins
Cohesion Bureau Tel: +44 (0)7483 284853
Investor relations and Communications
Mary-Ann Chang
About Thalia Therapeutics plc
Thalia Therapeutics plc is a pre-clinical biotech company focused on
developing innovative RNA therapeutics and novel delivery systems to address
high unmet needs in global healthcare.
RNA therapeutics is one of the most rapidly growing therapeutic sectors that
is set to impact the treatment of a wide range of diseases. Thalia
Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics
for cardiovascular and other diseases, as well as developing Nuvec®, its
proprietary gene delivery system, to further differentiate its therapeutic
assets.
Nuvec® addresses multiple challenges associated with RNA therapeutics
manufacturing and delivery, including the ability to deliver multiple RNA
therapies in a single particle, ease of manufacturing, protection of the RNA
payload to enable oral delivery, avoidance of unwanted immune responses, and
excellent stability and storage.
For further information visit www.thaliatx.com (http://www.thaliatx.com)
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAGPUQUAUPQGUW
Copyright 2019 Regulatory News Service, all rights reserved